Edward T. Anderson - 30 Jun 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: LYRA
Reported as of: 30 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jul 2023, 21:46:49 UTC
Prior SEC filing: 22 Jun 2023
Next SEC filing: 19 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Jason Cavalier, Attorney-in-Fact for Edward T. Anderson

Key filing fact

Edward T. Anderson filed Form 4 for Lyra Therapeutics, Inc. (LYRA) on 05 Jul 2023.

Key facts

This page summarizes Edward T. Anderson's Form 4 filing for Lyra Therapeutics, Inc. (LYRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jul 2023, 21:46.

Change

Previous filing in this sequence was filed on 22 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYRA transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 30 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $4.11
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.